Watch our capabilities presentation to learn how our integrated CDMO solutions accelerate immune cell therapy development from early-phase to commercial readiness.
May 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring...
Kincell Bio’s infographic distills the critical milestones shaping a cell therapy program’s journey from IND filing to full commercial supply. Explore how our integrated development,...
Learn MoreExplore how disciplined analytics accelerate every stage of cell therapy development. Our infographic traces the escalating rigor from exploring feasibility in preclinical studies to fully...
Learn MoreThe Chemistry, Manufacturing, and Controls (CMC) section of a cell therapy Investigational New Drug (IND) application is crucial in demonstrating to the FDA and other...
Read MoreAssay development is essential to cell therapy success—ensuring consistency, precision, and product effectiveness. But for complex cell-based assays, early-phase innovators often face high costs and...
DownloadYou have time, money, and expertise invested in your cell therapy program—let us help you bring it to market. Learn how Kincell is well-positioned to...
DownloadMay 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring...
Read More
1622 NW 55th Place
Gainesville, FL 32653
20 TW Alexander Dr, Suite 130
RTP, NC 27703
